April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Intravitreal Infusion of Ranibizumab with an Infusion Pump in Rabbits
Author Affiliations & Notes
  • Roberto Gonzalez-Soto
    Ophthalmology, Doheny Eye Institute, Los Angeles, California
  • Rodrigo A. Brant-Fernandes
    Ophthalmology, Doheny Eye Institute, Los Angeles, California
  • Mark S. Humayun
    Ophthalmology, Doheny Eye Institute, Los Angeles, California
    Replenish Inc, Pasadena, California
  • Rohit Varma
    Ophthalmology, Doheny Eye Institute, Los Angeles, California
  • Michelle Journey
    Replenish Inc, Pasadena, California
  • Sean Caffey
    Replenish Inc, Pasadena, California
  • Footnotes
    Commercial Relationships  Roberto Gonzalez-Soto, Replenish Inc. (F); Rodrigo A. Brant-Fernandes, Replenish Inc. (F); Mark S. Humayun, Replenish Inc (F, I, P); Rohit Varma, Replenish Inc (F); Michelle Journey, Replenish Inc (F, E, P); Sean Caffey, Replenish Inc (I, P)
  • Footnotes
    Support  Replenish Inc
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3246. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Roberto Gonzalez-Soto, Rodrigo A. Brant-Fernandes, Mark S. Humayun, Rohit Varma, Michelle Journey, Sean Caffey; Intravitreal Infusion of Ranibizumab with an Infusion Pump in Rabbits. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3246.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate intravitreal infusion of Ranibizumab in rabbitsinjected with intravitreal vascular endothelial growth factor(VEGF-A).


Four rabbits underwent intravitreal injection of 0.1ml of 10µg/0.1mlof VEGF-A on day 0. At day 3, all animals underwent intravitreallyinjection as follows: 1 rabbit underwent bolus injection of50µl of Ranibizumab (0.5mg/0.05ml), 2 rabbits were infusedover 30 minutes with 50µl of ranibizumab (0.5mg/0.05ml)using an external infusion pump, the fourth rabbit served asthe control and was infused with 50µl of balanced salinesolution over a period of 30 minutes. Fluorescein angiography(FA) and Optical Coherence Tomography (OCT) were performed onday 0, 3 and 7 to assess the action of VEGF and the differentmethods of intravitreal drug delivery.


When compared against control infusion of saline, the intravitrealinfusion of Ranibizumab over a period of 30 minutes and thesingle bolus injection of Ranibizumab were more effective inreducing the effects on the retinal vasculature. Moreover, theinfusion of Ranibizumab was similar in its effect to the bolusadministration of Ranibizumab.


These results show that a slower more prolonged infusion ofthe same volume and concentration of intravitreal Ranibizumabis equivalent to a bolus injection in this animal model. Furtherstudies are required to study in detail the posology of intravitrealRanibizumab administration which could guide different drugdelivery platforms.  


Keywords: retinal neovascularization 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.